NASDAQ: VALNValneva Se Stock
$7.75+0.01 (+0.13%)
Updated Apr 24, 2024
VALN Price
$7.75
Fair Value Price
-$5.74
Market Cap
$538.28M
52 Week Low
$6.58
52 Week High
$17.05
P/E
-4.88x
P/B
3.86x
P/S
4.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$167.08M
Earnings
-$112.70M
Gross Margin
34.4%
Operating Margin
-48.99%
Profit Margin
-66%
Debt to Equity
2.59
Operating Cash Flow
-$224M
Beta
1.06
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
VALN Overview
Valneva SE develops prophylactic vaccines for infectious diseases. Offerings include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine, DUKORAL, an oral vaccine for the prevention of diarrhea, and VLA2001, a vaccine candidate for SARS-CoV-2. Valneva SE collaborates with Pfizer to co-develop its Lyme disease vaccine and Instituto Butantan for the manufacturing of a single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VALN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VALN ($7.75) is overvalued by 235.13% relative to our estimate of its Fair Value price of -$5.74 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VALN ($7.75) is not significantly undervalued (235.13%) relative to our estimate of its Fair Value price of -$5.74 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VALN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VALN due diligence checks available for Premium users.
Be the first to know about important VALN news, forecast changes, insider trades & much more!
VALN News
Valuation
VALN fair value
Fair Value of VALN stock based on Discounted Cash Flow (DCF)
Price
$7.75
Fair Value
-$5.74
Undervalued by
235.13%
VALN ($7.75) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VALN ($7.75) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VALN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VALN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.88x
Industry
15.69x
Market
41.27x
VALN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.86x
Industry
5.86x
VALN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VALN's financial health
Profit margin
Revenue
$46.6M
Net Income
-$35.7M
Profit Margin
-76.8%
VALN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VALN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$511.2M
Liabilities
$368.7M
Debt to equity
2.59
VALN's short-term assets ($285.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VALN's short-term assets ($285.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VALN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$72.9M
Investing
-$18.1M
Financing
$41.0M
VALN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VALN vs Biotech Stocks
Valneva Se Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.